COPENHAGEN, SEPTEMBER 06, 2016 – AntibioTx has been invited to present recent positive results with ATx201 at the ‘2nd Inflammatory Skin Disease Summit’ symposium in New York the 16-20th November 2016.
The ‘2nd Inflammatory Skin Disease Summit’ is a symposium that directly addresses and describes new developments and therapies for key inflammatory skin diseases, such as psoriasis, atopic dermatitis and an increasing number of other inflammatory conditions.
The main purpose of the symposium is to update practicing dermatologist, MD-scientists and researchers in the field of treating skin diseases. The Symposium will feature internationally recognized researchers and will provide new research within skin infections and guidelines for future treatments improving clinical outcomes for the patients.
This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.
EasyBlog
This is some blog description about this site
AntibioTx Invited to Publish ATx201 Results at the ‘2nd Inflammatory Skin Disease Summit’ (New York)
News
09 February 2021
07 January 2021
28 October 2020
21 October 2020
25 August 2020
13 August 2020
22 July 2020
21 July 2020
01 July 2020
01 July 2020
02 April 2020
01 November 2019
01 July 2019
07 February 2019
13 November 2018
29 October 2018
30 July 2018
26 October 2017
24 March 2017
15 March 2017
19 September 2016
06 September 2016
19 August 2016
07 August 2016
07 April 2016
22 March 2016